Posted by shellson2 on 12th of Feb 2025 at 11:03 am
SENS--EU compliance may be next trigger for
stock
Eversense 365 is the world's first and only one
year CGM, which was approved by the United States (US) Food and
Drug Administration in September of 2024 and launched across the
country in October of the same year.
The Eversense 365 CE Mark submission was prepared
in compliance with the EU Medical Device Regulation (MDR) and,
upon approval, would enable the commercialization of Eversense 365
in European Union (EU) member countries by Senseonics' commercial
partner, Ascensia Diabetes Care. Following CE Mark approval
in Europe, the Company plans to distribute the Eversense 365
System in Germany, Italy, Spain (including Andorra), Poland,
Switzerland and Sweden.
"Completing the CE Mark submission for Eversense
365 brings us a step closer to improving lives and health outcomes
for patients in Europe. Given the success we have had to date with
the US launch of Eversense 365 by our partner, Ascensia, we look
forward to the opportunity to offer a ‘once a year' solution for
glucose control to the millions of people living with diabetes in
the European Union," said Tim Goodnow, PhD, President and Chief
Executive Officer of Senseonics.
SENS--.93 pre-market.
I try to follow as much biotech as possible...this is ...
Posted by shellson2 on 17th of Jan 2025 at 09:24 am
SENS--.93 pre-market.
SENS-- See my previous posts. Now at
Posted by shellson2 on 24th of Jan 2025 at 09:46 am
SENS--
See my previous posts.
Now at 1.08, heavy volume.
SENS-- New 52wk today, vol is
Posted by shellson2 on 12th of Feb 2025 at 10:58 am
SENS--
New 52wk today, vol is above average. Their next business update could be very meaningful. Will dig for that info.
SENS--EU compliance may be next
Posted by shellson2 on 12th of Feb 2025 at 11:03 am
SENS--EU compliance may be next trigger for stock
Eversense 365 is the world's first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year.
The Eversense 365 CE Mark submission was prepared in compliance with the EU Medical Device Regulation (MDR) and, upon approval, would enable the commercialization of Eversense 365 in European Union (EU) member countries by Senseonics' commercial partner, Ascensia Diabetes Care. Following CE Mark approval in Europe, the Company plans to distribute the Eversense 365 System in Germany, Italy, Spain (including Andorra), Poland, Switzerland and Sweden.
"Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for patients in Europe. Given the success we have had to date with the US launch of Eversense 365 by our partner, Ascensia, we look forward to the opportunity to offer a ‘once a year' solution for glucose control to the millions of people living with diabetes in the European Union," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
Senseonics Holdings, Inc. Schedules Fourth
Posted by shellson2 on 13th of Feb 2025 at 11:56 am
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
Up 15%, way above volume
Posted by shellson2 on 13th of Feb 2025 at 09:44 am
Up 15%, way above volume